GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+10.61%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$484M
AUM Growth
+$484M
(+16%)
Cap. Flow
+$82.3M
Cap. Flow
% of AUM
17.02%
Top 10 Holdings %
Top 10 Hldgs %
51.89%
Holding
57
New
15
Increased
16
Reduced
7
Closed
15
Top Buys
| 1 |
RAPT Therapeutics
RAPT
|
$22.2M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$17.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$15.9M |
| 4 |
OPTN
OptiNose
OPTN
|
$14.6M |
| 5 |
Viking Therapeutics
VKTX
|
$12.2M |
Top Sells
| 1 |
Relmada Therapeutics
RLMD
|
$18.9M |
| 2 |
Galapagos
GLPG
|
$13.1M |
| 3 |
Alkermes
ALKS
|
$12.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$10.4M |
| 5 |
Travere Therapeutics
TVTX
|
$10.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Erasca
ERAS
$445M
| $6.63M | 1.3% | +1,538,461 | New | +$6.63M |
|
|
ICPT
27
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $6.54M | 1.28% | 528,850 +423,850 | +404% | +$5.24M |
|
28
Acumen Pharmaceuticals
ABOS
$82.4M
| $6.03M | 1.18% | 1,116,581 -83,419 | -7% | -$450K |
|
|
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $6.03M | 1.18% | +133,000 | New | +$6.03M |
|
|
VERV
30
DELISTED
Verve Therapeutics
VERV
| $5.81M | 1.14% | +300,000 | New | +$5.81M |
|
|
ALBO
31
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $5.78M | 1.13% | +267,283 | New | +$5.78M |
|
32
Larimar Therapeutics
LRMR
$310M
| $5.26M | 1.03% | 1,273,635 +138,635 | +12% | +$573K |
|
33
UroGen Pharma
URGN
$900M
| $4.97M | 0.97% | 560,000 -313,424 | -36% | -$2.78M |
|
34
Precision BioSciences
DTIL
$57.8M
| $4.52M | 0.89% | 3,801,305 +1,090,500 | +40% | +$1.3M |
|
|
GRCL
35
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $4.51M | 0.88% | 1,962,399 +1,513,350 | +337% | +$3.48M |
|
36
Generation Bio
GBIO
$40.4M
| $4.02M | 0.79% | 1,022,537 +197,460 | +24% | +$776K |
|
37
Evolus
EOLS
$494M
| $1.43M | 0.28% | +190,329 | New | +$1.43M |
|
|
38
Alkermes
ALKS
$4.78B
| $1.21M | 0.24% | 46,185 -461,315 | -91% | -$12.1M |
|
39
Immunic
IMUX
$80.9M
| $885K | 0.17% | +632,184 | New | +$885K |
|
40
AnaptysBio
ANAB
$569M
| $465K | 0.09% | +15,000 | New | +$465K |
|
|
41
BridgeBio Pharma
BBIO
$9.89B
| – | – | -1,050,000 | Closed | -$10.4M |
|
42
Dianthus Therapeutics
DNTH
$759M
| – | – | -1,019,091 | Closed | -$1.44M |
|
43
89bio
ETNB
$1.34B
| – | – | -955,000 | Closed | -$5.53M |
|
|
44
Galapagos
GLPG
$2.07B
| – | – | -306,411 | Closed | -$13.1M |
|
45
Immunocore
IMCR
$1.62B
| – | – | -78,527 | Closed | -$3.69M |
|
46
Madrigal Pharmaceuticals
MDGL
$9.76B
| – | – | -95,500 | Closed | -$6.21M |
|
47
Milestone Pharmaceuticals
MIST
$156M
| – | – | -674,656 | Closed | -$6.2M |
|
48
Nektar Therapeutics
NKTR
$568M
| – | – | -447,820 | Closed | -$1.43M |
|
49
NovoCure
NVCR
$1.38B
| – | – | 0 | – | – |
|
50
Rocket Pharmaceuticals
RCKT
$354M
| – | – | 0 | – | – |
|